Stoneridge Investment Partners’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Stoneridge Investment Partners’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-18,684	Closed	-$26K	–	287
2017 Q3	$26K	Hold	18,684	–	–	﹤0.01%	236
2017 Q2	$28K	Sell	18,684 -38,722	-67%	-$83.1K	﹤0.01%	249
2017 Q1	$148K	Buy	57,406 +16,399	+40%	+$37.9K	0.02%	294
2016 Q4	$105K	Hold	41,007	–	–	0.01%	280
2016 Q3	$127K	Sell	41,007 -192	-0.5%	-$598	0.02%	257
2016 Q2	$132K	Hold	41,199	–	–	0.02%	273
2016 Q1	$128K	Sell	41,199 -15,556	-27%	-$50.8K	0.02%	279
2015 Q4	$228K	Sell	56,755 -7,637	-12%	-$35.2K	0.03%	254
2015 Q3	$295K	Sell	64,392 -800	-1%	-$4.19K	0.04%	240
2015 Q2	$338K	Buy	65,192 +18,465	+40%	+$111K	0.04%	236
2015 Q1	$293K	Buy	46,727 +1,069	+2%	+$6.17K	0.03%	234
2014 Q4	$287K	Buy	+45,658	New	+$278K	0.04%	221
2014 Q2	–	Sell	-43,136	Closed	-$1.03M	–	262
2014 Q1	$1.03M	Buy	+43,136	New	+$625K	0.2%	90

Other funds holding ECYT

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stoneridge Investment Partners's ECYT Position: Q4 2017 in Review

Stoneridge Investment Partners sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2017, closing a stake of 18,684 shares — an estimated $26K sold.

Stoneridge Investment Partners first reported a position in ECYT in Q1 2014 and held it in 13 quarters. The position peaked at $1.03M in Q1 2014. 71 funds tracked by Wall St. Rank hold ECYT as of Q4 2017.

Stoneridge Investment Partners reported no remaining Endocyte, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
Stoneridge Investment Partners sold 18,684 Endocyte, Inc. Common Stock shares in Q4 2017, an estimated $26K.
Stoneridge Investment Partners first reported a position in Endocyte, Inc. Common Stock in Q1 2014 and held it in 13 quarters.
Stoneridge Investment Partners's Endocyte, Inc. Common Stock position peaked at $1.03M in Q1 2014.
71 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2017.

Based on Stoneridge Investment Partners's 13F filing for Q4 2017, filed 5 Feb 2018.